Epkinly Wins Health Canada Approval for Follicular Lymphoma
ABBV sits 39% above its 52-week low of $190.75.
Summary
Health Canada approved Epkinly for adults with follicular lymphoma, expanding the drug's market into Canada. This is the first approval for Epkinly in this indication in Canada, adding a new revenue stream for AbbVie. The approval follows recent European approvals for Epkinly in other lymphoma settings, showing continued regulatory momentum. AbbVie's stock is trading near its 52-week high, and this approval supports the growth narrative for its oncology portfolio.
At the time of this announcement, ABBV was trading at $264.91 on NYSE in the Life Sciences sector, with a market capitalization of approximately $468.4B. The 52-week trading range was $190.75 to $269.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.